Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Bets Big On Moderna’s Preclinical Messenger RNA Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

The struggling pharma pays $240 million upfront for an exclusive collaboration to discover, develop and commercialize mRNA drugs in the cardiovascular, metabolic, renal and oncology spaces.

You may also be interested in...



Deal Watch: Anticipated Shire/Baxalta Merger Steals Attention From J.P. Morgan

Industry's leading deal-making stage shows continued focus on immuno-oncology, with activity by Merck, Novartis and AstraZeneca.

Deal Watch: Salix Merges With Italy’s Cosmo In Latest Tax-Inversion Play

A research agreement between AstraZeneca and Germany’s Max Planck Institute and a development pact between Portola and Daiichi Sankyo for an adverse-bleeding therapy highlight the week’s deal-making. In addition, HealthCare Royalty Partners announced a new royalty deal with Supernus and reworked its 2012 loan with Raptor, while GlobeImmune went public on its second IPO attempt.

Doubling Down On Cardiac Regeneration, AstraZeneca Forms Research Alliance With Shanghai SIBS

Going deeper into the cardiac regeneration space, AstraZeneca signed an agreement with SIBS to research coronary artery regeneration.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS075427

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel